GSK3B and non-small cell lung carcinoma: Furthermore, this investigation sought to elucidate the molecular mechanisms driving these phenotypic effects, specifically hypothesizing that the observed antitumor activity is mediated through the inhibition of the PI3K/AKT/GSK3β signaling cascade across distinct NSCLC subtypes.